Published in Immunology on April 01, 2011
Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer (2013) 1.35
Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016) 1.31
Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr Cancer Drug Targets (2011) 1.22
The immune system and inflammation in breast cancer. Mol Cell Endocrinol (2013) 1.12
Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat (2013) 1.04
Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer. Front Physiol (2013) 1.03
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. Clin Cancer Res (2016) 0.95
Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Ther (2014) 0.87
IFN-γ regulates survival and function of tumor-induced CD11b+ Gr-1high myeloid derived suppressor cells by modulating the anti-apoptotic molecule Bcl2a1. Eur J Immunol (2014) 0.86
The Microenvironmental Effect in the Progression, Metastasis, and Dormancy of Breast Cancer: A Model System within Bone Marrow. Int J Breast Cancer (2012) 0.86
Harnessing the immune system for the treatment of breast cancer. J Zhejiang Univ Sci B (2014) 0.85
Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology (2014) 0.82
Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination. Hum Vaccin Immunother (2014) 0.81
Molecular Mechanism and Potential Targets for Blocking HPV-Induced Lesion Development. J Oncol (2011) 0.80
Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells. Oncotarget (2015) 0.79
Properties of immature myeloid progenitors with nitric-oxide-dependent immunosuppressive activity isolated from bone marrow of tumor-free mice. PLoS One (2013) 0.79
In vitro exploration of a myeloid-derived suppressor cell line as vehicle for cancer gene therapy. Cancer Gene Ther (2016) 0.78
Inflammation and pancreatic cancer: disease promoter and new therapeutic target. J Gastroenterol (2013) 0.78
Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines. Cancer Immunol Immunother (2012) 0.78
Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer. Oncoimmunology (2016) 0.75
Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immunother Cancer (2017) 0.75
Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies. Oncotarget (2016) 0.75
L-Arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo. BMC Cancer (2016) 0.75
Taming immune suppressor: application of myeloid-derived suppressor cells in anti-cancer gene therapy. Transl Cancer Res (2017) 0.75
Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer. Oncol Lett (2017) 0.75
Downregulation of PTP1B and TC-PTP phosphatases potentiate dendritic cell-based immunotherapy through IL-12/IFNγ signaling. Oncoimmunology (2017) 0.75
Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science (1993) 19.80
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 7.02
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol (2007) 6.68
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol (2004) 5.73
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol (2005) 4.47
Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev (2008) 4.40
The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 4.37
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006) 4.20
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol (2003) 3.69
Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res (2007) 3.66
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol (2002) 3.56
A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci U S A (1996) 3.07
Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res (2009) 2.90
Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother (2005) 2.87
L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol (2003) 2.81
Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol (2008) 2.76
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood (1997) 2.66
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood (2007) 2.65
IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol (2009) 2.64
The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev (2003) 2.62
Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res (2008) 2.56
Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood (2007) 2.35
Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res (2008) 2.26
Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res (2007) 2.06
Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol (2008) 1.95
Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol (2010) 1.94
IL-12 receptor. II. Distribution and regulation of receptor expression. J Immunol (1992) 1.92
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res (2010) 1.92
T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-beta. Eur J Immunol (1994) 1.87
Expression cloning of a human IL-12 receptor component. A new member of the cytokine receptor superfamily with strong homology to gp130. J Immunol (1994) 1.84
Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. J Immunol (1996) 1.75
IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. J Immunol (1994) 1.75
Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J Immunol (2000) 1.68
IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol (2007) 1.67
IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. Immunity (1998) 1.64
Modulators of arginine metabolism support cancer immunosurveillance. BMC Immunol (2009) 1.61
Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother (2005) 1.40
Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J Immunol (2006) 1.37
Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int Immunopharmacol (2009) 1.37
Cloning and characterization of a mouse IL-12 receptor-beta component. J Immunol (1995) 1.37
IL-12 receptor. I. Characterization of the receptor on phytohemagglutinin-activated human lymphoblasts. J Immunol (1992) 1.32
Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett (2008) 1.31
Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res (2000) 1.30
IFN-gamma induces IL-12 mRNA expression by a murine macrophage cell line, J774. Biochem Biophys Res Commun (1994) 1.25
The importance of myeloid-derived suppressor cells in the regulation of autoimmune effector cells by a chronic contact eczema. J Immunol (2007) 1.21
Biological function and distribution of human interleukin-12 receptor beta chain. Eur J Immunol (1996) 1.17
Macrophages from IL-12p40-deficient mice have a bias toward the M2 activation profile. J Leukoc Biol (2002) 1.17
Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther (1996) 1.16
Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol Immunother (2008) 1.15
The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma. Cancer Res (2010) 1.14
Potential differentiation of tumor bearing mouse CD11b+Gr-1+ immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells. Biomed Res (2009) 1.07
Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci U S A (2007) 1.03
Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia (2004) 1.00
Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin. Cancer Res (2006) 0.98
Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis. Breast Cancer Res Treat (2008) 0.98
Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res (2002) 0.95
Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-gamma, and eradicate tumor cells. J Immunol (2005) 0.95
Conditions that diminish myeloid-derived suppressor cell activities stimulate cross-protective immunity. Infect Immun (2008) 0.92
Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol Immunother (1995) 0.89
IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion. Clin Exp Immunol (2004) 0.88
The regulation and biological activity of interleukin 12. Leuk Lymphoma (1998) 0.88
Antitumor and antiangiogenic effects of interleukin 12 gene therapy in murine head and neck carcinoma model. Auris Nasus Larynx (2004) 0.86
The inhibitory effect of cyclophosphamide-induced MAC-1+ natural suppressor cells on IL-2 and IL-4 utilization in MLR. Transplantation (1994) 0.86
Early exposure of high-dose interleukin-4 to tumor stroma reverses myeloid cell-mediated T-cell suppression. Gene Ther (2010) 0.85
Phorbol ester synergistically increases interferon regulatory factor-1 and inducible nitric oxide synthase induction in interferon-gamma-treated RAW 264.7 cells. Biochim Biophys Acta (2000) 0.80
IL-12 receptor (IL-12R) expression and accumulation of IL-12R beta 1 and IL-12R beta 2 mRNAs in CD4+ T cells by costimulation with B7-2 molecules. J Immunol (1998) 0.80
Effects of IL-12 gene therapy on spontaneous transgenic and transplanted breast tumors. Breast Cancer Res Treat (2007) 0.78
Intratumoral delivery of adenovirus-mediated interleukin-12 gene in mice with metastatic cancer in the liver. Hum Gene Ther (2002) 0.77
Combination therapy of androgen-independent prostate cancer using a prostate restricted replicative adenovirus and a replication-defective adenovirus encoding human endostatin-angiostatin fusion gene. Mol Cancer Ther (2006) 0.77
Inhibition of interferon-gamma signaling by a mercurio-substituted dihydropsoralen in murine keratinocytes. Biochem Pharmacol (2005) 0.76
Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med (2013) 24.88
Suicide rates in China, 1995-99. Lancet (2002) 9.40
Epidemiology of human infections with avian influenza A(H7N9) virus in China. N Engl J Med (2013) 7.52
Risk factors for suicide in China: a national case-control psychological autopsy study. Lancet (2002) 7.00
Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell (2003) 3.42
Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol (2004) 3.31
Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J (2004) 2.59
Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell (2007) 2.42
Regulation of polarized extension and planar cell polarity in the cochlea by the vertebrate PCP pathway. Nat Genet (2005) 2.36
The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol (2002) 2.03
Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol (2009) 1.91
An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. Cancer Cell (2010) 1.91
Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. Clin Infect Dis (2011) 1.87
Mitochondrial Hep27 is a c-Myb target gene that inhibits Mdm2 and stabilizes p53. Mol Cell Biol (2010) 1.86
Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood (2008) 1.83
HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res (2004) 1.83
Low-planned suicides in China. Psychol Med (2005) 1.81
Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol Cell Biol (2006) 1.76
Human regulatory T cells induce T-lymphocyte senescence. Blood (2012) 1.70
Mitochondrial p32 is a critical mediator of ARF-induced apoptosis. Cancer Cell (2008) 1.66
MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. J Biol Chem (2009) 1.63
Host cytokine storm is associated with disease severity of severe fever with thrombocytopenia syndrome. J Infect Dis (2012) 1.62
Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism. J Biol Chem (2006) 1.62
Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination. Mol Cell Biol (2003) 1.59
The seroprevalence of pandemic influenza H1N1 (2009) virus in China. PLoS One (2011) 1.54
Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11. Nat Med (2011) 1.52
Cochlear gap junctions coassembled from Cx26 and 30 show faster intercellular Ca2+ signaling than homomeric counterparts. Am J Physiol Cell Physiol (2005) 1.49
Circadian, day-of-week, and age patterns of the occurrence of acute coronary syndrome in Beijing's emergency medical services system. Am J Emerg Med (2010) 1.46
Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer (2004) 1.45
Putting a finger on growth surveillance: insight into MDM2 zinc finger-ribosomal protein interactions. Cell Cycle (2007) 1.43
Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer. J Immunol (2012) 1.38
In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur J Immunol (2011) 1.37
High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol (2003) 1.35
Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol Cell Biol (2006) 1.29
E3 ubiquitin ligase COP1 regulates the stability and functions of MTA1. Proc Natl Acad Sci U S A (2009) 1.28
HOXB13 homeodomain protein suppresses the growth of prostate cancer cells by the negative regulation of T-cell factor 4. Cancer Res (2004) 1.25
Nuclear import of the stem-loop binding protein and localization during the cell cycle. Mol Biol Cell (2005) 1.25
Ribosomal protein S9 is a novel B23/NPM-binding protein required for normal cell proliferation. J Biol Chem (2008) 1.24
Regulation of p53: a collaboration between Mdm2 and Mdmx. Oncotarget (2012) 1.24
Glycomic profiling of invasive and non-invasive breast cancer cells. Glycoconj J (2008) 1.24
The RP-Mdm2-p53 pathway and tumorigenesis. Oncotarget (2011) 1.23
Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res (2004) 1.20
Proteome reference map and comparative proteomic analysis between a wild type Clostridium acetobutylicum DSM 1731 and its mutant with enhanced butanol tolerance and butanol yield. J Proteome Res (2010) 1.19
Unlocking the Mdm2-p53 loop: ubiquitin is the key. Cell Cycle (2007) 1.16
Wnt signaling and a Hox protein cooperatively regulate psa-3/Meis to determine daughter cell fate after asymmetric cell division in C. elegans. Dev Cell (2006) 1.16
Hypoxia promotes interleukin-6 and -8 but reduces interleukin-10 production by placental trophoblast cells from preeclamptic pregnancies. J Soc Gynecol Investig (2005) 1.15
Use of national pneumonia surveillance to describe influenza A(H7N9) virus epidemiology, China, 2004-2013. Emerg Infect Dis (2013) 1.14
Essential role of the B23/NPM core domain in regulating ARF binding and B23 stability. J Biol Chem (2006) 1.13
Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem (2001) 1.13
Spaceflight transcriptomes: unique responses to a novel environment. Astrobiology (2012) 1.12
Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation. J Biol Chem (2011) 1.12
Engineering clostridium strain to accept unmethylated DNA. PLoS One (2010) 1.11
Tumor-derived γδ regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. J Immunol (2013) 1.10
Human tumor-infiltrating Th17 cells have the capacity to differentiate into IFN-γ+ and FOXP3+ T cells with potent suppressive function. Eur J Immunol (2011) 1.08
Guanine nucleotide depletion inhibits pre-ribosomal RNA synthesis and causes nucleolar disruption. Leuk Res (2007) 1.06
Designing and creating a modularized synthetic pathway in cyanobacterium Synechocystis enables production of acetone from carbon dioxide. Metab Eng (2012) 1.06
p53 Oligomerization is essential for its C-terminal lysine acetylation. J Biol Chem (2008) 1.06
Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC. Head Neck (2009) 1.05
EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res (2003) 1.05
Ribosomal proteins as unrevealed caretakers for cellular stress and genomic instability. Oncotarget (2014) 1.05
MTA1 coregulator regulates p53 stability and function. J Biol Chem (2009) 1.04
Prognostic evaluation of Nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer. Med Oncol (2014) 1.03
Novel prostate-specific promoter derived from PSA and PSMA enhancers. Mol Ther (2002) 1.03
B23 and ARF: friends or foes? Cell Biochem Biophys (2006) 1.03
Increased phospholipase A2 and thromboxane but not prostacyclin production by placental trophoblast cells from normal and preeclamptic pregnancies cultured under hypoxia condition. Placenta (2005) 1.03
The Ribosomal Protein-Mdm2-p53 Pathway and Energy Metabolism: Bridging the Gap between Feast and Famine. Genes Cancer (2011) 1.02
The Arabidopsis mediator complex subunit16 positively regulates salicylate-mediated systemic acquired resistance and jasmonate/ethylene-induced defense pathways. Plant Cell (2012) 1.02
Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer. Mol Cancer Ther (2012) 1.02
Novel redox potential-based screening strategy for rapid isolation of Klebsiella pneumoniae mutants with enhanced 1,3-propanediol-producing capability. Appl Environ Microbiol (2007) 1.00
Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther (2003) 1.00
Depletion of guanine nucleotides leads to the Mdm2-dependent proteasomal degradation of nucleostemin. Cancer Res (2009) 1.00
Evidence of endothelial dysfunction in preeclampsia: decreased endothelial nitric oxide synthase expression is associated with increased cell permeability in endothelial cells from preeclampsia. Am J Obstet Gynecol (2004) 0.99
Connexin29 is highly expressed in cochlear Schwann cells, and it is required for the normal development and function of the auditory nerve of mice. J Neurosci (2006) 0.99
Tip110, the human immunodeficiency virus type 1 (HIV-1) Tat-interacting protein of 110 kDa as a negative regulator of androgen receptor (AR) transcriptional activation. J Biol Chem (2004) 0.99
[A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy]. Zhonghua Yi Xue Za Zhi (2002) 0.99
Placental trophoblast-derived factors diminish endothelial barrier function. J Clin Endocrinol Metab (2004) 0.98
Increased Th17 cells in the tumor microenvironment is mediated by IL-23 via tumor-secreted prostaglandin E2. J Immunol (2013) 0.97
Synergistic effects of cisplatin chemotherapy and gold nanorod-mediated hyperthermia on ovarian cancer cells and tumors. Nanomedicine (Lond) (2014) 0.96
Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer. Cancer Res (2005) 0.96
p53-Inducible DHRS3 is an endoplasmic reticulum protein associated with lipid droplet accumulation. J Biol Chem (2011) 0.95
Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients. Am J Cancer Res (2011) 0.95
[11C]Choline as a PET biomarker for assessment of prostate cancer tumor models. Bioorg Med Chem (2004) 0.94
Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J Immunol (2003) 0.94
Controlling the oxidoreduction potential of the culture of Clostridium acetobutylicum leads to an earlier initiation of solventogenesis, thus increasing solvent productivity. Appl Microbiol Biotechnol (2011) 0.94
Acteoside protects human neuroblastoma SH-SY5Y cells against beta-amyloid-induced cell injury. Brain Res (2009) 0.93
Engineering the robustness of Clostridium acetobutylicum by introducing glutathione biosynthetic capability. Metab Eng (2011) 0.92
Diffusible signal factor-mediated quorum sensing plays a central role in coordinating gene expression of Xanthomonas citri subsp. citri. Mol Plant Microbe Interact (2012) 0.91
Use of oxidoreduction potential as an indicator to regulate 1,3-propanediol fermentation by Klebsiella pneumoniae. Appl Microbiol Biotechnol (2005) 0.91
Surgical margins and risk of locoregional recurrence in invasive breast cancer: an analysis of 10-year data from the Breast Cancer Treatment Quality Assurance Project. Breast (2013) 0.90
NFATc1 with AP-3 site binding specificity mediates gene expression of prostate-specific-membrane-antigen. J Mol Biol (2003) 0.90
The role of platelet CD154 in the modulation in adaptive immunity. Immunol Res (2007) 0.90
The Arabidopsis Mediator complex subunits MED14/SWP and MED16/SFR6/IEN1 differentially regulate defense gene expression in plant immune responses. Plant J (2013) 0.90
Transcriptome-wide analysis of dynamic variations in regulation modes of grapevine microRNAs on their target genes during grapevine development. Plant Mol Biol (2013) 0.89
Electrosorptive desalination by carbon nanotubes and nanofibres electrodes and ion-exchange membranes. Water Res (2008) 0.89
Clinical observations of mycophenolate mofetil therapy in refractory primary nephrotic syndrome. Nephrology (Carlton) (2003) 0.89